" class="no-js "lang="en-US"> Tiamat Sciences - Medtech Alert
Thursday, September 18, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Tiamat Sciences | Pharmtech Focus

Tiamat Sciences

About Tiamat Sciences

Tiamat Sciences

Tiamat is developing a plant molecular farming technology to manufacture affordable growth factors and other proteins that will make cell-based meats a mainstream alternative.

Our unique technology allows us superior flexibility with an affrodable production system and a scale-up potential up to the clean-meat requirements.

Related Story

Fundraising

 Female-Owned Biotech Startup Tiamat Sciences Raises $3 Million to Manufacture Plant-Based Biomolecules | Pharmtech Focus

Female-Owned Biotech Startup Tiamat Sciences Raises $3 Million to Manufacture Plant-Based Biomolecules

November 25 2021

Biotechnology startup Tiamat Sciences today announced its $3 million seed financing round led by Silicon Valley venture […]